Monocytes as Potential Mediators of Pathogen‐Induced T‐Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC)

Lilly Kristin Kunzmann, Tanja Schoknecht, Tobias Poch, Lara Henze, Stephanie Stein, Marvin Kriz, Ilka Grewe, Max Preti, Johannes Hartl, Nadine Pannicke, Moritz Peiseler, Marcial Sebode, Roman Zenouzi, Thomas Horvatits, Marius Böttcher, Britt‐Sabina Petersen, Christina Weiler‐Normann, Leonard U. Hess, Annika Elise Ahrenstorf, Sebastian Lunemann, Gloria Martrus, Lutz Fischer, Jun Li, Antonella Carambia, Johannes Kluwe, Samuel Huber, Ansgar W. Lohse, Andre Franke, Johannes Herkel, Christoph Schramm, Dorothee Schwinge – 23 January 2020

Hepatocellular Carcinoma—How to Determine Therapeutic Options

Neil Mehta – 22 January 2020 – Deciding on specific treatment strategies involves not only tumor stage, performance status, and severity of underlying liver disease, but additional factors such as biomarkers, organ availability, and radiographic tumor response to treatment. In this review, we present hepatocellular carcinoma (HCC) cases to highlight how to determine therapeutic options for HCC in specific scenarios, including resection versus liver transplant, choice of initial local regional treatment, tumor downstaging, and systemic therapies for advanced HCC.

Outcomes of Childhood Cholestasis in Alagille Syndrome: Results of a Multicenter Observational Study

Binita M. Kamath, Wen Ye, Nathan P. Goodrich, Kathleen M. Loomes, Rene Romero, James E. Heubi, Daniel H. Leung, Nancy B. Spinner, David A. Piccoli, Estella M. Alonso, Stephen L. Guthery, Saul J. Karpen, Cara L. Mack, Jean P. Molleston, Karen F. Murray, Philip Rosenthal, James E. Squires, Jeffrey Teckman, Kasper S. Wang, Richard Thompson, John C. Magee, Ronald J. Sokol, for the Childhood Liver Disease Research Network (ChiLDReN) – 22 January 2020 – Alagille syndrome (ALGS) is an autosomal dominant multisystem disorder with cholestasis as a defining clinical feature.

Deficits in Muscle Strength and Physical Performance Influence Physical Activity in Sarcopenic Children After Liver Transplantation

Poh Hwa Ooi, Vera C. Mazurak, Kerry Siminoski, Ravi Bhargava, Jason Y. K. Yap, Susan M. Gilmour, Diana R. Mager – 22 January 2020 – Sarcopenia is a muscle disease characterized by reduced skeletal muscle mass (SMM), muscle strength, and physical performance. Reduced SMM has been identified in children after liver transplantation (LT), but no information related to muscle strength/physical performance or lifestyle factors contributing to sarcopenia is available.

Subscribe to